Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215273 · ClinicalTrials.gov registry record · Phase 2
Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections
A Phase 2 study of Suspected Invasive Mould Infection, sponsored by Elion Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT07215273 is a Phase 2 study of Suspected Invasive Mould Infection that is actively recruiting participants, run by Elion Therapeutics. The registered enrollment target is 80 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT07215273, a Phase 2 study of Suspected Invasive Mould Infection, is actively recruiting participants, sponsored by Elion Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if EL219 is safe and effective compared to the standard of care for early treatment of suspected invasive mould infection.
Conditions Studied
Interventions
- DRUG EL219
- DRUG Antifungal Comparator
Study Locations (2)
Missouri
- Washington U. - St Louis
Texas
- U. of Texas, MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215273
The ClinicalTrials.gov registry entry for NCT07215273 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elion Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Suspected Invasive Mould Infection appearing as the primary indexed condition, and to 2 interventions - of which EL219 is the first listed.
NCT07215273 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT07215273 about?
NCT07215273 is a clinical study titled "Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections". The purpose of this study is to determine if EL219 is safe and effective compared to the standard of care for early treatment of suspected invasive mould infection.
What is the current status of trial NCT07215273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-02. Estimated completion is 2026-11.
What conditions does trial NCT07215273 study?
This clinical trial studies the following conditions: Suspected Invasive Mould Infection.
What interventions are being tested in trial NCT07215273?
The interventions under investigation include: EL219 (DRUG), Antifungal Comparator (DRUG).
Who is sponsoring clinical trial NCT07215273?
This trial is sponsored by Elion Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215273 being conducted?
This trial has 2 study locations across Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.